Werewolf Therapeutics (HOWL) Non-Current Assets (2020 - 2026)
Werewolf Therapeutics (HOWL) posted quarterly Non-Current Assets of $1.3 million for Q2 2026, down 89.59% year-over-year from $12.1 million in Q2 2025, and down 86.4% on a QoQ basis from $9.3 million in Q1 2026.
Werewolf Therapeutics (HOWL) Non-Current Assets (2020 - 2026) Analysis & Trends
Werewolf Therapeutics has reported Non-Current Assets for 7 years, with the latest figure at $1.3 million in Q2 2026.
- Non-Current Assets for Q2 2026 came in at $1.3 million, down 89.59% year-over-year; the trailing twelve-month figure through Jun 2026 was $32.8 million (down 38.05% YoY), and the FY2025 annual result was $10.8 million, down 22.02% from the prior year.
- Non-Current Assets eased to $1.3 million in Q2 2026, from $9.3 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $38.5 million in Q1 2023 and troughed at $1.3 million in Q2 2026.
- A 5-year average of $20.4 million and a median of $17.1 million in 2022 frame the typical range for Non-Current Assets.
- The widest annual swing landed in 2022, when Non-Current Assets soared 424.73%; it then sank 89.59% in 2026.
- A 5-year view of Non-Current Assets shows it stood at $20.0 million in 2022, then soared by 81.91% to $36.5 million in 2023, then plunged by 61.98% to $13.9 million in 2024, then retreated by 22.02% to $10.8 million in 2025, then tumbled by 88.32% to $1.3 million in 2026.
- Per Business Quant data, the three most recent Non-Current Assets figures were $1.3 million in Q2 2026, $9.3 million in Q1 2026, and $10.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.35 Bn | 131.49 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 86.24 Bn | 78.25 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.08 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.83 Bn | 53.69 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 27.95 Bn | 9.56 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.50 Bn | 26.34 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.44 Bn | - | 18.06 Bn |
| 10 | Werewolf Therapeutics | 43.97 Mn | 43.97 Mn | - | 1.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.26 Mn |
| Mar 31, 2026 | 9.29 Mn |
| Dec 31, 2025 | 10.81 Mn |
| Sep 30, 2025 | 11.45 Mn |
| Jun 30, 2025 | 12.13 Mn |
| Mar 31, 2025 | 12.78 Mn |
| Dec 31, 2024 | 13.86 Mn |
| Sep 30, 2024 | 14.20 Mn |
| Jun 30, 2024 | 14.92 Mn |
| Mar 31, 2024 | 35.32 Mn |
| Dec 31, 2023 | 36.46 Mn |
| Sep 30, 2023 | 37.13 Mn |
| Jun 30, 2023 | 37.84 Mn |
| Mar 31, 2023 | 38.51 Mn |
| Dec 31, 2022 | 20.05 Mn |
| Sep 30, 2022 | 20.84 Mn |
| Jun 30, 2022 | 21.16 Mn |
| Mar 31, 2022 | 19.20 Mn |
| Dec 31, 2021 | 18.18 Mn |
| Sep 30, 2021 | 3.97 Mn |